Product Detail


Share to:
facebook sharing button
twitter sharing button
line sharing button
wechat sharing button
linkedin sharing button
pinterest sharing button
whatsapp sharing button
sharethis sharing button

Cas No. 59107-51-6, 1-Amino-8-chloronaphthalenewith

  • 59107-51-6

  • C10H8ClN

  • 177.63

  • 1.289±0.06

  • 98% min (HPLC)

  • 93-94

  • Non-small-cell carcinoma

  • Adagrasib

  • 5/17/2037 (Adagrasib)

  • KRAS G12C

  • 10 g

  • ISO9001

  • CDMO



With its selective inhibition of mutant KRAS G12C proteins, Adagrasib shows tremendous potential to revolutionize cancer treatment. This cutting-edge drug delivers remarkable efficacy and tolerability, offering hope to patients with limited treatment options. By adding Adagrasib to your pharmaceutical portfolio, you can contribute to the fight against KRAS G12C mutated cancers and make a meaningful impact on patients' lives.